$358.07
-0.70-0.2%
Últ. Act.: Oct 2, 9:30 AM
$351.99
-6.78-1.89%
BeOne Medicines (ONC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BeOne Medicines (ONC) publicó su última previsión de agosto 5, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $6.6B - $6.8B para el período.
En comparación con la previsión anterior, BeOne Medicines elevado redujo su previsión de ingresos desde un rango anterior de $6.3B - $6.5B.
BeOne Medicines ha emitido 7 actualizaciones de orientación entre el febrero 27, 2025 y el agosto 5, 2026. During this period, the company raised its outlook 3 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.44 | $0.79 | $1.42 | $0.80 |
| Actual | $3.84 | $3.24 | $1.95 | $2.65 |
| Surprise | +166.7% | +310.1% | +37.3% | +231.3% |
| Revenue | ||||
| Estimate | $1.59B | $1.44B | $1.45B | $1.35B |
| Actual | $1.71B | $1.51B | $1.50B | $1.41B |
| Surprise | +7.19% | +5.00% | +3.10% | +4.26% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.94 | $1.65 | $2.96 | $3.31 |
| Revenue | ||||
| Consensus | $1.76B | $1.79B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $3.84 | $1.44 | 166.7 % |
| Q1 | May 6, 2026 | $3.24 | $0.79 | 310.1 % |
| Q4 | Feb 26, 2026 | $1.95 | $1.42 | 37.3 % |
| Q3 | Nov 6, 2025 | $2.65 | $0.80 | 231.3 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $1.71B | $1.59B | 7.19 % |
| Q1 | May 6, 2026 | $1.51B | $1.44B | 5.00 % |
| Q4 | Feb 26, 2026 | $1.50B | $1.45B | 3.10 % |
| Q3 | Nov 6, 2025 | $1.41B | $1.35B | 4.26 % |